Morgan Stanley Windtree Therapeutics Inc Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.16 - $281.7 $143 - $252,403	-896 Reduced 95.83%	39 $0
Q3 2022 Nov 14, 2022	BUY	$0.3 - $306.0 $276 - $281,826	921 Added 6578.57%	935 $0
Q2 2022 Oct 27, 2022	SELL	$0.38 - $1.14 $954 - $2,864	-2,513 Reduced 99.45%	14 $0
Q2 2022 Aug 15, 2022	SELL	$0.38 - $1.14 $954 - $2,864	-2,513 Reduced 99.45%	14 $0
Q1 2022 Oct 27, 2022	BUY	$0.94 - $1.6 $2,362 - $4,020	2,513 Added 17950.0%	2,527 $3,000
Q1 2022 May 13, 2022	BUY	$0.94 - $1.6 $2,361 - $4,019	2,512 Added 16746.67%	2,527 $3,000
Q4 2021 Feb 14, 2022	SELL	$1.4 - $2.31 $14 - $23	-10 Reduced 40.0%	15 $0
Q3 2021 Nov 15, 2021	BUY	$1.66 - $2.27 $41 - $56	25 New	25 $0

4.09K

Ticker WINT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,627,900
Market Cap $22.1M
Description
Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.